The drugs reshaping obesity treatment may also be reshaping sleep medicine. A systematic review and meta-analysis published in Sleep and Breathing in 2026 has produced the first pooled analysis of randomized controlled trials examining whether GLP-1 receptor agonists — the drug class behind Ozempic, Wegovy, and Mounjaro — can reduce the severity of obstructive sleep apnea.
The answer, across four trials and multiple endpoints, is a clear yes. But the size of the effect varies dramatically depending on which drug is used.
The Headline Numbers
The meta-analysis combined data from four randomized, placebo-controlled trials comparing GLP-1 receptor agonists to placebo in adults with obstructive sleep apnea. The pooled results:
- Apnea-hypopnea index (AHI): Reduced by a mean of 13.89 events per hour (p < 0.01) — a clinically meaningful improvement that could shift many patients from severe to moderate, or moderate to mild, disease categories
- Body weight: Decreased by a mean of 12.46 kg (roughly 27 pounds)
- Systolic blood pressure: Dropped by 4.86 mmHg
- Serious adverse events: No significant increase compared to placebo
Tirzepatide Outperforms Liraglutide by a Wide Margin
The most striking finding was the subgroup analysis comparing the two main drugs studied. Liraglutide (marketed as Saxenda for weight loss) produced a moderate AHI reduction of 5.20 events per hour. Tirzepatide — a dual GLP-1/GIP receptor agonist sold as Mounjaro for diabetes and Zepbound for obesity — achieved a reduction of 23.80 events per hour.
The difference between the two drugs was statistically significant (p < 0.0001), suggesting that tirzepatide's dual-receptor mechanism or its greater weight-loss potency translates directly into superior airway outcomes.
This aligns with earlier data from the SURMOUNT-OSA trial, published in the New England Journal of Medicine, which found tirzepatide reduced AHI by 25 to 29 events per hour over 52 weeks — along with an 18 to 20% reduction in body weight.
More Than Just Weight Loss
The obvious question is whether these drugs help sleep apnea simply because patients lose weight, or whether something more specific is happening. The meta-analysis does not resolve this definitively, but several lines of evidence suggest the effect is not purely weight-driven.
Tirzepatide's blood pressure reduction (5.76 mmHg systolic) exceeded liraglutide's (4.00 mmHg), and emerging research points to additional mechanisms including reduced fat deposition around the upper airway, anti-inflammatory effects that may decrease tissue swelling, and modulation of autonomic nervous system activity during sleep.
A separate meta-analysis in the journal SLEEP reached similar conclusions, finding that GLP-1 receptor agonists significantly improved AHI in adults with moderate-to-severe OSA.
The Practical Reality
GLP-1 drugs are not without drawbacks. Gastrointestinal side effects — nausea, diarrhea, vomiting, constipation, and acid reflux — were consistently more common in treatment groups across all trials. The drugs also require ongoing use; stopping treatment typically leads to weight regain and, presumably, a return of apnea severity.
Cost remains a barrier. Tirzepatide and semaglutide carry list prices exceeding $1,000 per month in the United States, and insurance coverage for obesity indications is inconsistent. The FDA approved tirzepatide (as Zepbound) for obesity-associated obstructive sleep apnea in June 2024, but that approval does not guarantee payer coverage.
What This Means for Patients
For the estimated 30 million Americans with obstructive sleep apnea, GLP-1 drugs represent a genuinely new treatment category — the first pharmacological option that targets both the metabolic driver (excess weight) and the downstream consequence (airway collapse) with quantifiable efficacy.
This does not mean GLP-1 drugs replace CPAP, oral appliances, or surgical interventions. Patients with severe OSA still need immediate airway management. But for the large population of patients with obesity-related moderate sleep apnea who struggle with CPAP adherence — roughly half abandon it within 90 days — these drugs offer an evidence-based alternative or complement that now has meta-analytic support.
The question for sleep medicine is no longer whether GLP-1 drugs work for apnea. It is how to integrate them into treatment algorithms, how to identify which patients benefit most, and how to make them accessible beyond those who can afford out-of-pocket costs.
